These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28108772)

  • 1. Peritherapeutic Serum p53 Antibody Titers are Predictors of Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Surgery.
    Yamashita K; Makino T; Tanaka K; Yamasaki M; Yamamoto M; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    World J Surg; 2017 Jun; 41(6):1566-1574. PubMed ID: 28108772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
    Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
    Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.
    Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T
    World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study.
    Takashi S; Satoshi Y; Akihiko O; Naoya Y; Yusuke T; Kentaro M; Yu O; Yasuaki N; Koichi Y; Takashi F; Ryo O; Isamu H; Chikara K; Kosuke N; Yasuhiro T; Kazuhiko Y; Hideaki S
    Esophagus; 2021 Jan; 18(1):65-71. PubMed ID: 32715348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma.
    Kochi R; Yajima S; Nanami T; Suzuki T; Oshima Y; Tokura N; Takatsuka J; Funahashi K; Tochigi N; Shimada H
    Clin J Gastroenterol; 2018 Aug; 11(4):278-281. PubMed ID: 29497977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of perioperative change in serum p53 antibody titers in esophageal squamous cell carcinoma.
    Haneda R; Mayanagi S; Inoue M; Ishii K; Morita Y; Kikuchi H; Hiramatsu Y; Takeuchi H; Tsubosa Y
    Esophagus; 2023 Oct; 20(4):669-678. PubMed ID: 37212971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.
    Chung Y; Law S; Kwong DL; Luk JM
    Dis Esophagus; 2011 Jan; 24(1):49-55. PubMed ID: 20807231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma.
    Shimada H; Nabeya Y; Okazumi S; Matsubara H; Funami Y; Shiratori T; Hayashi H; Takeda A; Ochiai T
    Surgery; 2002 Jul; 132(1):41-7. PubMed ID: 12110794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
    Ji WH; Jiang YH; Ji YL; Li B; Mao WM
    Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular factors and criteria for predicting the response to neoadjuvant treatment in patients with esophageal squamous cell carcinoma (ESCC) -- responder/non-responder.
    Predescu D; Gheorghe M; Boeriu M; Constantin A; Iosif C; Anghel R; Constantinoiu S
    Chirurgia (Bucur); 2012; 107(5):583-90. PubMed ID: 23116831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
    Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma.
    Takahashi K; Miyashita M; Nomura T; Makino H; Futami R; Kashiwabara M; Katsuta M; Tajiri T
    Dis Esophagus; 2007; 20(2):117-22. PubMed ID: 17439594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy.
    Chen YF; Li Q; Chen DT; Pan JH; Chen YH; Wen ZS; Zeng WA
    Cancer Biomark; 2016 Jun; 17(1):89-96. PubMed ID: 27314297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
    Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
    Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 Protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma--preliminary report.
    Nasierowska-Guttmejer A; Szawłowski A; Jastrzebska M; Jeziorski K; Radziszewski J
    Dis Esophagus; 1999; 12(2):128-31. PubMed ID: 10466045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma.
    Duan H; Zhang X; Wang FX; Cai MY; Ma GW; Yang H; Fu JH; Tan ZH; Meng YQ; Fu XY; Ma QL; Lin P
    World J Gastroenterol; 2015 May; 21(18):5591-7. PubMed ID: 25987784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.